Cargando…

Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression

BACKGROUND: Osteoporosis is a common phenomenon in HIV patients on tenofovir treatment, but its underlying mechanisms remain to be explored. METHODS: Quantitative real-time PCR was performed to analyze the expression of miR-302, miR-101, miR-145 and osteoclast-specific genes in the serum of HIV pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Wei, Li, Xing-fu, Ren, Dong-cheng, Song, Meng, Duan, Li, Liu, Jin-zhu, Zhan, Zi-rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908730/ https://www.ncbi.nlm.nih.gov/pubmed/33637048 http://dx.doi.org/10.1186/s10020-021-00276-5

Ejemplares similares

Madecassoside inhibits estrogen deficiency‐induced osteoporosis by suppressing RANKL‐induced osteoclastogenesis
por: Wang, Qingqing, et al.
Publicado: (2018)

BCI Suppresses RANKL-Mediated Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss
por: Cai, Chenhui, et al.
Publicado: (2021)

Cryptotanshinone Suppressed Postmenopausal Osteoporosis by Preventing RANKL-Mediated Osteoclastogenesis against Kidney Injury
por: Yang, Wenjiu, et al.
Publicado: (2022)

Icaritin ameliorates RANKL-mediated osteoclastogenesis and ovariectomy-induced osteoporosis
por: Huang, Jun-ming, et al.
Publicado: (2023)

Vps35 loss promotes hyperresorptive osteoclastogenesis and osteoporosis via sustained RANKL signaling
por: Xia, Wen-Fang, et al.
Publicado: (2013)

Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL-mediated NF-κB and JNK and their downstream signalling pathways
por: Huang, Xiao-Lin, et al.
Publicado: (2022)

Green tea (Camellia sinensis) aqueous extract alleviates postmenopausal osteoporosis in ovariectomized rats and prevents RANKL-induced osteoclastogenesis in vitro
por: Wu, Xin, et al.
Publicado: (2018)

Inhibiting Monoacylglycerol Lipase Suppresses RANKL-Induced Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss
por: Liu, Hui, et al.
Publicado: (2021)

Ginsenoside compound-K attenuates OVX-induced osteoporosis via the suppression of RANKL-induced osteoclastogenesis and oxidative stress
por: Ding, Lingli, et al.
Publicado: (2023)

Clomipramine causes osteoporosis by promoting osteoclastogenesis via E3 ligase Itch, which is prevented by Zoledronic acid
por: Li, Xing, et al.
Publicado: (2017)

Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities
por: Liu, Yuhao, et al.
Publicado: (2019)

QKI deficiency leads to osteoporosis by promoting RANKL-induced osteoclastogenesis and disrupting bone metabolism
por: Du, Tianshu, et al.
Publicado: (2020)

Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL
por: Jang, Yuria, et al.
Publicado: (2021)

Mitf Induction by RANKL Is Critical for Osteoclastogenesis
por: Lu, Ssu-Yi, et al.
Publicado: (2010)

SPHK Inhibitors and Zoledronic Acid Suppress Osteoclastogenesis and Wear Particle-Induced Osteolysis
por: Gu, Minghui, et al.
Publicado: (2022)

Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo
por: Chen, Shuai, et al.
Publicado: (2015)

MCU Inhibitor Ruthenium Red Alleviates the Osteoclastogenesis and Ovariectomized Osteoporosis via Suppressing RANKL-Induced ROS Production and NFATc1 Activation through P38 MAPK Signaling Pathway
por: Wang, Yuxin, et al.
Publicado: (2022)

A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-κB pathways
por: Liu, Ying, et al.
Publicado: (2021)

The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat
por: Ashtar, Mohannad, et al.
Publicado: (2020)

Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
por: Qi, Guobin, et al.
Publicado: (2022)

Nardosinone Suppresses RANKL-Induced Osteoclastogenesis and Attenuates Lipopolysaccharide-Induced Alveolar Bone Resorption
por: Niu, Chenguang, et al.
Publicado: (2017)

Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss
por: Qi, Dahu, et al.
Publicado: (2021)

RANKL-induced DC-STAMP Is Essential for Osteoclastogenesis
por: Kukita, Toshio, et al.
Publicado: (2004)

TRPM7 Is Essential for RANKL-Induced Osteoclastogenesis
por: Yang, Yu-Mi, et al.
Publicado: (2013)

RANKL Signaling and Osteoclastogenesis Is Negatively Regulated by Cardamonin
por: Sung, Bokyung, et al.
Publicado: (2013)

Jatrorrhizine Hydrochloride Suppresses RANKL-Induced Osteoclastogenesis and Protects against Wear Particle-Induced Osteolysis
por: Li, Hui, et al.
Publicado: (2018)

Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB
por: Quan, Gui-Hua, et al.
Publicado: (2015)

Tetrandrine inhibits RANKL-induced osteoclastogenesis by promoting the degradation of TRAIL
por: Li, Jiarui, et al.
Publicado: (2022)

Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis
por: Li, Chang-hong, et al.
Publicado: (2021)

Orientin suppresses osteoclastogenesis and ameliorates ovariectomy‐induced osteoporosis via suppressing ROS production
por: Zheng, Yan, et al.
Publicado: (2023)

Pasteurella multocida Toxin Triggers RANKL-Independent Osteoclastogenesis
por: Chakraborty, Sushmita, et al.
Publicado: (2017)

Galangin suppresses RANKL‐induced osteoclastogenesis via inhibiting MAPK and NF‐κB signalling pathways
por: Li, Xiucheng, et al.
Publicado: (2021)

Corrigendum: Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis
por: Li, Chang-hong, et al.
Publicado: (2023)

Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo
por: Peng, Jiaxuan, et al.
Publicado: (2020)

Cytochalasin Z11 inhibits RANKL-induced osteoclastogenesis via suppressing NFATc1 activation
por: Wang, Lu, et al.
Publicado: (2019)

Melatonin inhibits osteoclastogenesis via RANKL/OPG suppression mediated by Rev‐Erbα in osteoblasts
por: Tian, Yihao, et al.
Publicado: (2022)

Inhibitory effects of ChondroT and its constituent herbs on RANKL-induced osteoclastogenesis
por: Guo, Rui Hong, et al.
Publicado: (2019)

Attenuated RANKL-induced cytotoxicity by Portulaca oleracea ethanol extract enhances RANKL-mediated osteoclastogenesis
por: Erkhembaatar, Munkhsoyol, et al.
Publicado: (2015)

Theaflavin-3, 3′-Digallate Suppresses RANKL-Induced Osteoclastogenesis and Attenuates Ovariectomy-Induced Bone Loss in Mice
por: Ai, Zexin, et al.
Publicado: (2020)

How zoledronic acid improves osteoporosis by acting on osteoclasts
por: Wang, Biao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2f0j7ne2om11urnpgpb1q70vkr